Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
Liposarcoma (LPS) is a rare cancer that can acquire resistance to chemotherapy. Here, the authors map super-enhancers in LPS, finding BET-protein dependent mechanisms that can be targeted by a BET protein degrader, which also can overcome acquired resistance to chemotherapy in LPS.
Enregistré dans:
Auteurs principaux: | Ye Chen, Liang Xu, Anand Mayakonda, Mo-Li Huang, Deepika Kanojia, Tuan Zea Tan, Pushkar Dakle, Ruby Yu-Tong Lin, Xin-Yu Ke, Jonathan W. Said, Jianxiang Chen, Sigal Gery, Ling-Wen Ding, Yan-Yi Jiang, Angela Pang, Mark Edward Puhaindran, Boon Cher Goh, H. Phillip Koeffler |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/737f0325add94122b8c3c1a96fabd32f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
par: Qianqian Wang, et autres
Publié: (2017) -
Liposarcoma suprarrenal derecho
par: Tarigo-Casella,Nicolás, et autres
Publié: (2018) -
Liposarcoma retroperitoneal gigante
par: Pacheco,Sergio, et autres
Publié: (2017) -
Paraneoplastic retinopathy associated with retroperitoneal liposarcoma
par: Mineo Kondo, et autres
Publié: (2010) -
Integrated exome and RNA sequencing of dedifferentiated liposarcoma
par: Makoto Hirata, et autres
Publié: (2019)